UroGen Pharma Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" UroGen Pharma stock.
View analyst ratings for UroGen Pharma or view top-rated stocks.

Wall Street analysts have given UroGen Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but UroGen Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

UroGen Pharma Ltd. (NASDAQ:URGN) released its quarterly earnings results on Monday, November, 9th. The company reported ($1.31) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($1.47) by $0.16. The company had revenue of $3.46 million for the quarter, compared to analysts' expectations of $3.21 million.
View UroGen Pharma's earnings history.

UroGen Pharma's stock was trading at $23.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, URGN stock has decreased by 14.2% and is now trading at $20.46.
View which stocks have been most impacted by COVID-19.

3 brokerages have issued 1-year price targets for UroGen Pharma's shares. Their forecasts range from $26.00 to $57.00. On average, they anticipate UroGen Pharma's stock price to reach $42.25 in the next year. This suggests a possible upside of 106.5% from the stock's current price.
View analysts' price targets for UroGen Pharma or view top-rated stocks among Wall Street analysts.

Some companies that are related to UroGen Pharma include Zymeworks (ZYME), Zentalis Pharmaceuticals (ZNTL), uniQure (QURE), Kronos Bio (KRON), Heron Therapeutics (HRTX), Antibe Therapeutics (ATBPD), Antibe Therapeutics (ATBPD), Antibe Therapeutics (ATBPF), Frequency Therapeutics (FREQ), Nkarta (NKTX), Praxis Precision Medicines (PRAX), PMV Pharmaceuticals (PMVP), Travere Therapeutics (TVTX), Olema Pharmaceuticals (OLMA) and Amneal Pharmaceuticals (AMRX).
View all of URGN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu BioScience (AYTU).

(URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

UroGen Pharma trades on the NASDAQ under the ticker symbol "URGN."

UroGen Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.32%), Credit Suisse AG (5.36%), Phoenix Holdings Ltd. (3.92%), Horton Capital Management LLC (1.87%), Northern Trust Corp (1.15%) and Nuveen Asset Management LLC (0.95%). Company insiders that own UroGen Pharma stock include Elizabeth A Barrett, Mark Schoenberg, Peter P Pfreundschuh and Stephen Mullennix.
View institutional ownership trends for UroGen Pharma.

URGN stock was sold by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd., Nuveen Asset Management LLC, JPMorgan Chase & Co., Northern Trust Corp, SG Americas Securities LLC, State of Wisconsin Investment Board, Shikiar Asset Management Inc., and Barclays PLC. Company insiders that have sold UroGen Pharma company stock in the last year include Mark Schoenberg, Peter P Pfreundschuh, and Stephen Mullennix.
View insider buying and selling activity for UroGen Pharma or view top insider-selling stocks.

URGN stock was purchased by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Annandale Capital LLC, Russell Investments Group Ltd., BlackRock Inc., Renaissance Technologies LLC, Bank Hapoalim BM, Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD, and Trexquant Investment LP. Company insiders that have bought UroGen Pharma stock in the last two years include Elizabeth A Barrett, and Mark Schoenberg.
View insider buying and selling activity for UroGen Pharma or or view top insider-buying stocks.

Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of URGN stock can currently be purchased for approximately $20.46.

UroGen Pharma has a market capitalization of $427.55 million and generates $20,000.00 in revenue each year. The company earns $-105,150,000.00 in net income (profit) each year or ($5.12) on an earnings per share basis.

UroGen Pharma employs 187 workers across the globe.

The official website for UroGen Pharma is www.urogen.com.

UroGen Pharma is headquartered at 400 Alexander Park, Princeton NJ, 08540.

UroGen Pharma's mailing address is 400 Alexander Park, Princeton NJ, 08540. The company can be reached via phone at 646-768-9780 or via email at [email protected]